eHealth Ventures
VC Fund
Tel Aviv, Israel
eHealth Ventures is a consortium conceived to provide incubation services to promising early-stage healthcare technology companies in Israel. The Government of Israel offers a unique opportunity for leverage by providing significant financial incentives to incubators assisting technology start-ups capitalizing on Israel's extraordinarily richtalent pool.The next Tender is expected the second half of 2014. eHealth Ventures will apply for an eight-year license under the program. They are seeking qualified individual and institutional investors who would like to participate in this extraordinary, highly leveraged opportunity.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 32%
- Fund size:
- $30M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries eHealth Ventures invests in
Stages eHealth Ventures invests in
Countries eHealth Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Talor Sax
|
|||
Kobi Inbar
|
|||
Lior Shalev
|
|||
Ophir Shahaf
|
|||
Steve Shapiro
|
Investment Focus
Industry
- Health Care 26 (68%)
- Health Diagnostics 10 (26%)
- Medical Device 9 (24%)
- Artificial Intelligence 8 (21%)
- Software 5 (13%)
Stage
- Pre-Seed 18 (47%)
- Seed 14 (37%)
- Grant 1 (3%)
- Series A 1 (3%)
- Venture - Series Unknown 1 (3%)
Country
- Israel 25 (66%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Talor Sax
Managing Partner
|
Managing Partner | Total investments: 2 | Find email | |
|
Kobi Inbar
Head of eHealth Ventures Physician-Entrepreneurs Acceleration Program
|
Head of eHealth Ventures Physician-Entrepreneurs Acceleration Program | Total investments: 0 | Find email | |
|
Lior Shalev
Partner
|
Partner | Total investments: 0 | Find email | |
|
Ophir Shahaf
VP Business Development
|
VP Business Development | Total investments: 7 | Find email | |
|
Steve Shapiro
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
FIZE Medical
|
Fize Medical offers novel tools for reliable, monitoring of patient, its initial solution is a way to track renal output continuously. | $14M / Series A / Dec 24, 2024 | |
DreaMed Diabetes
|
DreaMed Diabetes is a medical device, SaaS company providing personalized diabetes treatment optimization solutions. The company was established in 2014, commercializing the first artificial pancreas technology which was published in the NEJM. Eversince, DreaMed Diabetes has been vigorously working on decision support tools in the diabetesmanagement space and became the first and only company in the world to receive FDA clearance for a decision support system using data from CGM/SMBG and insulin pumps. We offer a clinically proven decision support system for insulin titration in type 1 diabetes patients. Our Advisor Pro software was created by diabetes professionals and is based on real-world experience, turbo-charged by artificial intelligence. Using it, any healthcare professional can analyze patient data in seconds and advise on the optimal treatment plan. By frequent titration changes and online monitoring, we allow patients better treatment thus by lowering their A1C levels and risk for complications. Using the Advisor Pro physicians and nurses can provide true patient-centered care and everyone can receive the same top-level of treatment – wherever they are and whoever their caregiver is. | $3M / Venture - Series Unknown / Aug 19, 2024 | |
AccuLine
|
AccuLine is a digital healthcare company, which was founded with the vision to saves the lives of millions of people worldwide. AccuLine is developing CORA—a smart, accurate, and easy to use exam for the early detection of coronary artery disease. The clinically validated CORA evaluates a patient's risk of having coronary artery diseasethrough advanced analysis and detection of two newly discovered biomarkers in the heart’s electrical activity. CORA’s early detection will assist in the prevention of sudden cardiac deaths, while lowering costs of cardiovascular related illness. | $3.5M / Seed / May 01, 2024 | |
|
Nitur
|
Nitur is developing COPatch, a flexible patch equipped with ultrasound micro-transducers that can be easily and quickly placed on a patient’s chest. It provides continuous and accurate hemodynamic data. The ultrasound signals are processed by an AI machine in order to provide an accurate continuous cardiac output parameters. | $800K / Pre-Seed / Mar 01, 2024 | |
Insight Axis
|
Insight Axis uses EEG Analytics proposes to create an algorithm-based platform for predicting the compliance and responsiveness of neuropsychiatric patients to different medications. The platform will enable physicians to predict the patient’s neurobiological response to specific medications before treatment has even begun. The platform willcreate patient-specific brainwave signatures using data from EEG results. Using this Brain Signature, the algorithm will be able to calculate neuro-markers in the brain and then categorically assess the potential of drug suitability for the individual patient. | $800K / Pre-Seed / Feb 01, 2024 | |
OtiSense
|
Acute Otitis Media (AOM) causes poor conductance of the Chorda Tympani nerve, resulting in its functional impairment, interpreted by the brain as impaired taste sensation. During the inflammation period of AOM, there is a difference in the taste sensation at the two sides of the tongue.While the unaffected side transmits normal tastesensation, on the affected side there is decrease in taste transmission and sensation. The taste buds can be activated with electrical stimulation and the gustatory evoked potentials (GEPs) can be recorded at the cortical gustatory cortex using EEG.Given the observation that AOM is usually unilateral and that the taste sensation on the side of the infection is damaged, electrical stimulation of both sides of the tongue should resulted in different GEPs reading from the infected side compared to the intact side, detecting the presence of AOM.Talma Medical develops a breakthrough innovative technology for accurate clinical diagnostic at home. An over the counter, easy to use and mostly accurate device will make a revolution in the way AOM is diagnosed. | $800K / Pre-Seed / Feb 01, 2024 | |
|
Wizermed
|
Wizermed provides a remedy for migraine relief. The technology empowers migraine sufferers to prepare and take preventive steps based on AI-based migraine attack forecasts by constantly monitoring data from the user's smartwatch sensors. | $800K / Pre-Seed / Aug 19, 2023 | |
|
ToDx
|
ToDX product is an at home diagnostic platform that will perform tests with comparable accuracy to PCR results. The first clinical application of this at-home diagnostic platform will be applied to STI’s (sexually transmitted infections), including chlamydia, gonorrhea, and trichomoniasis. ToDX plans to widen the clinical applications to therespiratory infections, including diagnosis of papillomavirus strains and the diagnosis of upper respiratory virus strains. | $800K / Pre-Seed / Jul 24, 2023 | |
SmarTest
|
Startest is developing an easy-to-use test to detect blood glucose levels in prediabetic patients. The test is designed to be for one-time use and is compatible with an online platform. The test has the same precision as a regular glucose meter, but is administered through Smartest’s patent needle mechanism, which is less painful to patients thantraditional blood glucose testing. | $800K / Pre-Seed / Jul 01, 2023 | |
QLOG
|
QLOG is a creator of a healthcare management platform that provides detailed visibility and control over processes and assets. The platform of the company uses the internet of things as a data-collection grid to record the process of what happened, the individual who handled it, the position of the equipment, and the recent developments of theequipment, allowing healthcare businesses to reduce the overheads and difficulties of legacy systems. | $2.5M / Seed / Jun 27, 2023 | |
| See all 38 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does eHealth Ventures invest in?
eHealth Ventures invests primarily in Health Care, Health Diagnostics and Medical Device startups, most often at Pre-Seed and Seed stage. Most of the 38 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact eHealth Ventures?
Public channels for eHealth Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at eHealth Ventures?
The team at eHealth Ventures includes Talor Sax (Managing Partner), Kobi Inbar (Head of eHealth Ventures Physician-Entrepreneurs Acceleration Program) and Lior Shalev (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
